![3-{[3-(Trifluoromethyl)benzyl]oxy}benzoic acid - chemical structure image](https://media.scbt.com/product/3-3-trifluoromethyl-benzyloxybenzoic-acid-structure_22_83_b_228345.jpg)
![3-{[3-(Trifluoromethyl)benzyl]oxy}benzoic acid - chemical structure image](https://media.scbt.com/product/3-3-trifluoromethyl-benzyloxybenzoic-acid-structure_22_83_t_228345.jpg "Molecular structure of 3-{[3-(Trifluoromethyl)benzyl]oxy}benzoic acid")
3-{[3-(Trifluoromethyl)benzyl]oxy}benzoic acid
QUICK LINKS
Prostaglandin I2 sodium (PGI2) is primarily synthesized in macrovascular endothelial cells. It may act to induce vasodilation and inhibit platelet aggregation, as well as demonstrate fibrinolytic and cytoprotective activity. Prostaglandin I2 sodium binding to the G-protein coupled IP1 receptor (PGI2 receptor) is responsible for inhibition of platelet aggregation and vasodilation activity. In addition, Prostaglandin I2 sodium greatly increases cAMP concentrations. Prostaglandin I2 sodium is 30 times more active than PGE1(sc-201223), and 10 times more active than PGD2(sc-201221) however, it is a relatively unstable eicosanoid, with a half-life of about 2 minutes under physiological conditions. Analogues such as Iloprost (sc-205349) have been developed with superior stability and similar potency for IP receptors.
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
3-{[3-(Trifluoromethyl)benzyl]oxy}benzoic acid, 500 mg | sc-312192 | 500 mg | $180.00 |